The approval from TGA was a major milestone for Skin Elements, and allows it to execute its commercialisation strategy.
In a major development, Skin Elements (ASX:SKN) has just secured a Therapeutic Goods Administration (TGA) registration for its Invisi Shield SuprCuv as a hospital-grade disinfectant product.
The Invisi Shield SuprCuvr product has previously been confirmed by independent laboratory testing to have a 99.99999% effectiveness against COVID-19.
Skin Elements’ own research indicates the product is the first and only approved disinfectant globally with a 99.99999% efficacy against COVID-19.
With the TGA registration, Invisi Shield SuprCuvr will now be approved for use in hospitals and aged-care homes — places that are restricted to using only TGA registered disinfectants.
Separately, Skin Elements also says the product has been certified by the NASAA (National Association for Sustainable Agriculture Australia) Organic and Biodynamic Standard.
This certification is a recognition that reflects the company’s commitment to its natural and organic philosophy across its full skincare product range.
Today’s development is a major milestone in the product’s development timeline, which now paves the way for mass commercialisation.
“We see the potential to provide an efficacious, 100% plant-based disinfectant in large commercial settings as a major opportunity for Invisi Shield SuprCuvr and the company,” says Skin Element’s Executive Chairman, Peter Malone.
“With TGA registration now in place, we plan to aggressively drive our sales and distribution plans for Invisi Shield SuprCuvr with the aim of delivering revenues to the company, and value for shareholders.”
Highly effective against COVID-19
Skin Elements explains that the 99.99999% efficacy rate was calculated as a Log 7 reduction, and represents a substantial difference from what is currently on the market.
In terms of infection control, log reduction conveys the level of effectiveness in reducing pathogens.
The greater the log reduction, the more effective the product is at killing bacteria and other pathogens that can cause infections.
In scientific terms, a Log 7 reduction is 10 times greater than Log 6 reduction (99.9999%), 100 times greater than Log 5 (99.999%), 1,000 times greater than Log 4 (99.99%) and 10,000 times greater than Log 3 (99.9%).
The product itself has been the result of more than 15 years research and development by the Skin Elements’ team in the area of plant-based ingredients and antimicrobials.
It is Australian made, and derived from 100% plant-based, proprietary formula that is biodegradable, vegan, non-corrosive, non- flammable, and is cruelty-free (not tested on animals).
According to Skin, the Invisi Shield SuprCuvr does not contain benzalkonium chloride, hydrogen peroxides, quaternary ammonium compounds, bleach/chlorine compounds or other typical chemical ingredients commonly found in disinfectant products.
Next step: commercialisation
With the TGA registration, Invisi Shield SuprCuvr can now be used in many settings, including hospitals and aged-care homes.
Other sectors that might also benefit from the product are hotels, offices, airports, public transport hubs, as well as home use.
The TGA registration also allows Skin Elements to make detailed and specific product and label claims on the product.
Importantly, it also paves the way for Skin Elements to commence its commercialisation and growth strategy.
A big part of the go-to market strategy involves pursuing commercial-scale sales and distribution opportunities with distributors and other potential sales partners.
In particular, Skin Elements is looking for partners who stipulate TGA registration as a pre-requisite in the disinfectant products they deal in.
Apart from Invisi Shield SuprCuvr, the company has also launched a range of other alcohol-free, all-natural sanitiser products in the market.
This includes products such as the Soléo Organics natural and organic sunscreen, PapayaActivs natural therapeutics skincare, and Elizabeth Jane Natural Cosmetics brand.
In April, Skin Elements closed a $20m equity facility deal that would see the company fully funded for the next three years as it embarks on the commercialisation strategy.
This article was originally posted by Stock Head.